Sort
30,917 grants matching “tumor microenvironment”
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2021 · AI
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2020 · AI
Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities
$413,506Jlenia Guarnerio · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Training in Cellular & Molecular Mechanisms of Tumor Rejection
$413,502Olivera J Finn · University Of Pittsburgh At Pittsburgh · T32 · FY2010 · CA
Therapeutic resistance and aggressive malignancy in glioblastomas: the contribution of GTP metabolism through regulation by IMPDH2
$413,481Atsuo Sasaki · University Of Cincinnati · R01 · FY2021 · CA
ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE
$413,478Heather L Stevenson · University Of Texas Med Br Galveston · R01 · FY2024 · DK
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer
$413,430Frank A Sinicrope · Mayo Clinic Rochester · R01 · FY2020 · CA
ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology
$413,428Carin Marie-Louise Sentman · Celdara Medical, Llc · R43 · FY2010 · HL
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
$413,399Zhihui Wang · Methodist Hospital Research Institute · R01 · FY2021 · CA
The Role of Cancer-Associated Fibroblasts in Thyroid Carcinoma
$413,396Vivian Lee Weiss · Vanderbilt University Medical Center · R01 · FY2022 · CA
The role of P16Ink4a in adult skeletal muscle stem cells
$413,367Andrew S Brack · University Of California, San Francisco · R01 · FY2021 · AR
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$413,341Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$413,325Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$413,325Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2021 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
Adipocyte regulation of tumor survival in metastatic prostate cancer: new targets for therapy
$413,294Izabela Podgorski · Wayne State University · R01 · FY2021 · CA
Disparities in Immuno-oncology Outcomes in Detroit (DIODE)
$413,265Kristen S. Purrington · Wayne State University · P20 · FY2025 · CA
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma
$413,248Damian J. Green · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
$413,174Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Metabolic Control of Immune Suppression in Gliomas
$413,173Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2018 · NS
Metabolic Control of Immune Suppression in Gliomas
$413,173Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2019 · NS
TECH Core
$413,131Kevin William Eliceiri · University Of Minnesota · U54 · FY2022 · CA
Reprogramming the Tumor Microenvironment in Ovarian Cancer
$413,104David D Schlaepfer · University Of California, San Diego · R01 · FY2021 · CA